The ARSD Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of A-549 cells carrying targeted disruption of the ARSD gene, which encodes arylsulfatase D. This knockout model is generated using CRISPR/Cas9-mediated gene disruption to eliminate ARSD function, providing a versatile tool for loss-of-function studies in a lung carcinoma background. The polyclonal nature of the product ensures genetic diversity while maintaining consistent ARSD knockout across the population, suitable for population-level phenotypic analyses.
The A-549 cell line is a widely used model of human lung adenocarcinoma, originally derived from the lung carcinoma of a 58-year-old Caucasian male. These cells exhibit an epithelial morphology, express wild-type p53, and grow as an adherent monolayer. A-549 cells are extensively employed in cancer research, drug testing, and viral studies, making them a relevant host for investigating the role of ARSD in oncogenic processes and therapeutic responses.
ARSD is a sulfatase enzyme that catalyzes the hydrolysis of sulfate esters and is predicted to be active in the endoplasmic reticulum (ER). It presumably participates in the degradation of sulfated glycosaminoglycans and other substrates, contributing to cellular sulfate metabolism. The enzyme may require sulfatase-modifying factors such as SUMF1 and ER chaperones like ERp44 for activation. ARSD functions within broader sulfatase-mediated hydrolysis and glycosaminoglycan degradation pathways, linking ER-associated degradation to sulfate recycling. Knockout of ARSD disrupts arylsulfatase D activity, potentially altering sulfate ester hydrolysis in the ER and impacting downstream metabolic processes.
In the A-549 lung cancer context, ARSD knockout offers a unique model to dissect sulfatase biology in malignancy. Lung adenocarcinoma cells may rely on specific sulfatase activities for proliferation, migration, or drug resistance; thus, ARSD disruption can unveil its contribution to these phenotypes. The model also enables investigation of ER stress responses and sulfate metabolism, pathways often dysregulated in cancer. By eliminating ARSD, researchers can assess the enzyme’s role in maintaining cellular homeostasis and evaluate potential therapeutic targets within sulfatase networks.
This knockout cell population is suitable for a range of applications, including studying sulfatase function in lung cancer, ER stress signaling, and sulfate metabolism. Typical assays include sulfatase activity measurements, western blotting for protein expression changes, RT-qPCR for transcript analysis, immunofluorescence for subcellular localization, and flow cytometry for phenotypic profiling. Functional studies can incorporate cell viability, migration/invasion, and drug sensitivity assays to explore the impact of ARSD loss on A-549 cell behavior. This resource aids dissection of ARSD-mediated pathways in cancer biology. For additional technical details and ordering information, please contact Ascent Research.
